— Pruritus Pipeline Market Companies Involved in Therapeutics Development are Albireo AB, Alveonix AG, Amorepacific Corporation, Asana BioSciences, LLC, Cara Therapeutics, Inc., Chugai Pharmaceutical Co., Ltd., Creabilis SA, ELORAC, Inc., Faes Farma, S.A., GlaxoSmithKline Plc, Hydra Biosciences, Inc., LEO Pharma A/S, Merck & Co., Inc., NeRRe Therapeutics Ltd, Nippon Shinyaku Co., Ltd., Patara Pharma, Inc., Phosphagenics Limited, RDD Pharma Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Shionogi & Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Teikoku Pharma USA, Inc., Tioga Pharmaceuticals, Inc., Trevi Therapeutics, Inc. and Vanda Pharmaceuticals Inc.
The report provides comprehensive information on the therapeutics under development for Pruritus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects.
Purchase a copy of this research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=701990
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
- The report provides a snapshot of the global therapeutic landscape of Pruritus
- The report reviews pipeline therapeutics for Pruritus by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Pruritus therapeutics and enlists all their major and minor projects
- The report assesses Pruritus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Pruritus
Complete research report of 123 pages with TOC is available at http://www.rnrmarketresearch.com/pruritus-pipeline-review-h2-2016-market-report.html
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Pruritus
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pruritus pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Name: Ritesh Tiwari
Email: Send Email
Organization: RnR Market Research
Address: UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune, Maharashtra 411013, India
Phone: +1888 391 54 41
Release ID: 134846